Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus DEFLAZACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus DEFLAZACORT.
A-METHAPRED vs DEFLAZACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."